A 2015 review found that the use of high CBD-to-THC strains of cannabis showed significantly fewer positive symptoms such as delusions and hallucinations, better cognitive function and both lower risk for developing psychosis, as well as a later age of onset of the illness, compared to cannabis with low CBD-to-THC ratios. A 2014 Cochrane review found that research was insufficient to determine the safety and efficacy to using cannabis to treat schizophrenia or psychosis. As of 2017, the molecular mechanisms for the anti-inflammatory and possible pain relieving effects of cannabis are under preliminary research.
Topicals represent a newer emerging market in medical marijuana products geared toward health and beauty. Cannabinoids can be absorbed through the skin for certain therapeutic benefits without any psychoactivity. Additionally, the essential oils in hemp and cannabis provide many benefits for skin health. From moisturizers to shampoos and deodorants, medical cannabis products continue to diversify.
Elixinol has a wide range of products, but their CBD Tincture does the trick. It’s the cream of the crop regarding CBD oils and that reflects in its price. One dropper (1mg) from the 300 series contains 10mg of CBD. This allows you to get precise amounts of CBD and no guess work is required. Elixinol has received numerous awards for their products and extraction process.
His third question is whether cannabis serves as a gateway drug. There are two possibilities. The first is that marijuana activates certain behavioral and neurological pathways that ease the onset of more serious addictions. The second possibility is that marijuana offers a safer alternative to other drugs: that if you start smoking pot to deal with chronic pain you never graduate to opioids.
We need proper studies, the panel concluded, on the health effects of cannabis on children and teen-agers and pregnant women and breast-feeding mothers and “older populations” and “heavy cannabis users”; in other words, on everyone except the college student who smokes a joint once a month. The panel also called for investigation into “the pharmacokinetic and pharmacodynamic properties of cannabis, modes of delivery, different concentrations, in various populations, including the dose-response relationships of cannabis and THC or other cannabinoids.”
A hundred years ago, what Martin Lee describes, was common to all pharmaceuticals. Drugs were generally made from dried plants ( the Dutch word “Drug” derives from the word for “dry”) that a pharmacist ground into powder and extracted. Standardizing the growing conditions was difficult. Ultimately, standardization was a matter of isolating the active ingredient and making pure crystals of it, then weighing out the crystals milligram by milligram, to mix the finished medicine.
Then come Chapters 5 through 13, the heart of the report, which concern marijuana’s potential risks. The haze of uncertainty continues. Does the use of cannabis increase the likelihood of fatal car accidents? Yes. By how much? Unclear. Does it affect motivation and cognition? Hard to say, but probably. Does it affect employment prospects? Probably. Will it impair academic achievement? Limited evidence. This goes on for pages.
In 2019, the European Commission announced that CBD and other cannabinoids would be classified as "novel foods", meaning that CBD products would require authorization under the EU Novel Food Regulation stating: because "this product was not used as a food or food ingredient before 15 May 1997, before it may be placed on the market in the EU as a food or food ingredient, a safety assessment under the Novel Food Regulation is required." The recommendation – applying to CBD extracts, synthesized CBD, and all CBD products, including CBD oil – was scheduled for a final ruling by the European Commission in March 2019. If approved, manufacturers of CBD products would be required to conduct safety tests and prove safe consumption, indicating that CBD products would not be eligible for legal commerce until at least 2021.
CBD research is still in its infancy because both the substance itself and the cultivation of the plants from which it’s derived have long been illegal in the United States. And despite all those cookies you see for sale, CBD does seem to remain illegal, unless FDA approved. In December, hemp cultivation was legalized nationwide as a provision of the Agriculture Improvement Act of 2018. But the FDA released a statement explicating the agency’s stance on CBD’s legality: In short, the FDA does not recognize a distinction between cannabis- and hemp-derived CBD and, for the time being, considers both to be illegal—especially as a questionably safe food additive. Although CBD isn’t dangerous to healthy people, it can affect how the body metabolizes certain types of medication, which Blessing says could lead to overdose in some cases. (Because of the government shutdown, the FDA is unavailable to explain its stance or enforcement plans in further detail.)
Chronic pain: The body’s ECS plays a role in alleviating and managing pain, so CBD oil can work as a supplement for individuals with medical conditions that cause chronic pain, such as arthritis and multiple sclerosis. CBD oil also increases levels of adenosine in the brain; adenosine is a neurotransmitter that aids cardiovascular function and eases painful inflammation.
But experimental anxiety, which is when stressors are applied to make a volunteer feel anxious for a test, is different than clinical anxiety, and long-term, rigorous clinical trials are necessary to find CBD’s real-life effects on patients. Several are under way right now, including one Blessing is conducting at NYU, but the process of completing those, finding appropriate dosages, and creating a consistent drug that can meet Food and Drug Administration approval standards takes time. “Getting into the full pipeline of FDA approval is probably eight to 10 years away,” Blessing says.